Predominant infiltration of macrophages and CD8+ T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer
…, G Ishii, K Kubota, Y Murata, Y Naito… - … Journal of the …, 2008 - Wiley Online Library
BACKGROUND. The purpose of this study was to investigate whether tumor‐infiltrating
immune cells in biopsy specimens can be used to predict the clinical outcome of stage IV …
immune cells in biopsy specimens can be used to predict the clinical outcome of stage IV …
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast …
Background Antibody–drug conjugates have emerged as a powerful strategy in cancer therapy
and combine the ability of monoclonal antibodies to specifically target tumour cells with …
and combine the ability of monoclonal antibodies to specifically target tumour cells with …
Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial
…, A Spira, A Kawai, A Le Cesne, BA Van Tine, Y Naito… - Jama, 2020 - jamanetwork.com
Importance Patients with advanced soft tissue sarcoma (STS) have a median overall survival
of less than 2 years. In a phase 2 study, an overall survival benefit in this population was …
of less than 2 years. In a phase 2 study, an overall survival benefit in this population was …
[HTML][HTML] HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and …
…, YH Park, CH Lin, YS Lu, M Ono, T Ueno, Y Naito… - BMC medicine, 2022 - Springer
Background HER2-low breast cancer (BC) is currently an area of active interest. This study
evaluated the impact of low expression of HER2 on survival outcomes in HER2-negative non-…
evaluated the impact of low expression of HER2 on survival outcomes in HER2-negative non-…
Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis
…, Y Hozumi, M Tsuneizumi, N Kondo, Y Naito… - Breast cancer research …, 2014 - Springer
To define prognostic factors for breast cancer patients with brain metastases, compare their
clinical courses and prognoses according to breast cancer subtypes, and analyze the …
clinical courses and prognoses according to breast cancer subtypes, and analyze the …
Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population
Background The incidence of breast cancer among younger East Asian women has been
increasing rapidly over recent decades. This international collaborative study systemically …
increasing rapidly over recent decades. This international collaborative study systemically …
[HTML][HTML] Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1)
Y Naito, H Aburatani, T Amano, E Baba… - International Journal of …, 2021 - Springer
Background To promote precision oncology in clinical practice, the Japanese Society of
Medical Oncology, the Japanese Society of Clinical Oncology, and the Japanese Cancer …
Medical Oncology, the Japanese Society of Clinical Oncology, and the Japanese Cancer …
Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients
K Tamura, H Mukai, Y Naito, K Yonemori… - Cancer …, 2016 - Wiley Online Library
This phase I study in Japanese patients evaluated the safety, pharmacokinetics, and preliminary
efficacy of palbociclib, a highly selective and reversible oral cyclin‐dependent kinase 4/…
efficacy of palbociclib, a highly selective and reversible oral cyclin‐dependent kinase 4/…
[HTML][HTML] The Japanese breast cancer society clinical practice guidelines for systemic treatment of breast cancer, 2018 edition
…, Y Sagara, M Takada, T Takano, J Tsurutani, Y Naito… - Breast Cancer, 2020 - Springer
Purpose We present the English version of The Japanese Breast Cancer Society (JBCS)
Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. Methods The …
Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. Methods The …
[HTML][HTML] Recent progress and challenges in the diagnosis and treatment of gastrointestinal stromal tumors
T Nishida, S Yoshinaga, T Takahashi, Y Naito - Cancers, 2021 - mdpi.com
Simple Summary Gastrointestinal stromal tumors (GIST) are potentially malignant tumors and
require evidence-based surgical and/or medical treatment. Laparoscopy has similar safety …
require evidence-based surgical and/or medical treatment. Laparoscopy has similar safety …
